Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CVS Health (CVS) upgraded to Strong Buy from Buy at Needham by analyst Kevin Caliendo, who contended that the stock remains underowned and, unlike its peers, yet to rally beyond the expectations of benefits from the tax changes. The analyst says the company's multiple has remained constant despite the expansion in the rest of the pharma services industry, forecasting EPS growth of 8%-10% beyond the modeled $8 per share in 2019. 2. JetBlue (JBLU) upgraded to Overweight from Neutral at JPMorgan by analyst Jamie Bakier who said the company's costs are "gradually coming under control" and its balance sheet is "sound." The analyst also upgraded United Continental (UAL) to Overweight from Underweight, saying the shares are the "cheapest in the sector and among the most washed out, having declined the most from recent highs." 3. Gilead (GILD) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who said that tax reform could lower the company's tax rate to 22% in 2018 versus prior estimates of 28%. The analyst also raised her nonalcoholic steatohepatitis and JAK-1 probability of success estimates to 50% with both Phase 3 trials expected in the next 12 months. Further, Karnauskas expects Gilead's hepatitis C virus business to stabilize by mid-2018. 4. Intel (INTC) upgraded to Buy from Neutral at Citi by analyst Christopher Danely, who said overly conservative guidance and poor sentiment from years of underperformance should drive estimates and the stock higher in the near term. He believes management's "new habit" of conservative guidance is good for the stock. 5. Albemarle (ALB) upgraded to Buy from Neutral at UBS by analyst John Roberts, who said the stock is down 23% from the November high despite no change to the outlook for lithium. The analyst attributes the pullback to larger scale lithium expansion announcements and raising concerns of potential oversupply. He believes the market is pricing in 10% annual realized price declines for Albemarle over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Cantor Fitzgerald lowered the firm's price target on Intel to $40 from $45 and keeps a Neutral rating on the shares. Intel's report was not "ideal," and 1H24 trends are coming in worse than expected on broad-based weakness, resulting in a miss on the Q2 guidance, the analyst tells investors in a research note. The good news is that management reiterated its view for year over year growth in calendar 2024, implying a meaningful inflection in the back half of the year, the firm says. While Cantor continues to pull for Intel as the National Champion, the firm remains on the sidelines awaiting greater conviction on the reclaiming of market leadership across the company's various offerings.

Citi lowered the firm's price target on Intel to $35 from $40 and keeps a Neutral rating on the shares. Intel reported decent results but guided below consensus as strength from the PC end market was throttled by an issue in wafer assembly, the analyst tells investors in a research note. Citi's checks indicate Intel is on track to draw even with TSMC in manufacturing sometime next year, which is a positive. However, the company is guiding for well above seasonal growth in the second half of 2024, adds the firm.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Consensus $3.67. Sees FY24 product sales $27.1B-$27.5B.

Reports Q1 revenue $6.7B, consensus $5.92B. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August. New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024."

Pre-earnings options volume in Intel is normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 5.6%, or $1.96, after results are released. Median move over the past eight quarters is 7.8%.

Intel (INTC) is scheduled to report results of its fiscal first quarter after the market close on April 25, with a conference call scheduled for 5:00 pm ET. What to watch... To see the rest of the story go to thefly.com. See Story Here